论文部分内容阅读
目的探讨新辅助化疗对晚期卵巢癌的临床疗效。方法 2009年09月至2011年09月期间,我院诊治的80例卵巢癌患者,随机将其分为对照组(新辅助化疗后,再进行最大肿瘤减灭术)和观察组(最大肿瘤减灭术后,辅以铂类为主的化疗治疗),每组各40例。对两种治疗方法的临床疗效、毒副反应等情况进行观察和比较。结果与对照组总有效率相比(65.0%),治疗组的总有效率明显增高(87.5%),P<0.05,差异具有统计学意义。观察组的40例患者中,有3例出现并发症(7.5%)。对照组的40例患者中,有2例(5.0%)出现并发症,1例由于并发症导致死亡。结论新辅助化疗明显提高晚期卵巢癌患者的临床疗效,值得临床广泛推广。
Objective To investigate the clinical effect of neoadjuvant chemotherapy on advanced ovarian cancer. Methods Eighty patients with ovarian cancer diagnosed and treated in our hospital from September 2009 to September 2011 were randomly divided into control group (maximal tumor reduction after neoadjuvant chemotherapy) and observation group (maximal tumor reduction After surgery, supplemented by platinum-based chemotherapy), 40 cases in each group. Clinical efficacy of the two treatment methods, toxicity and other conditions were observed and compared. Results Compared with the total effective rate of the control group (65.0%), the total effective rate of the treatment group was significantly increased (87.5%), P <0.05, the difference was statistically significant. Of the 40 patients in the observation group, 3 developed complications (7.5%). Of 40 patients in the control group, 2 (5.0%) developed complications and 1 died of complications. Conclusion Neoadjuvant chemotherapy significantly improves the clinical efficacy of patients with advanced ovarian cancer, it is worth widely clinical promotion.